- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
Ajanta Pharma will participate in a one-on-one Analyst/Institutional Investor Meeting at the Jefferies India Forum on September 16, 2026. The company will also attend the PL Capital Mid & Small Cap Conference 2026 on September 28, 2026. Discussions at both events will be based strictly on already published information.
Ajanta Pharma promoter, Aayush Agrawal Trust, recently saw some movement in pledged shares. On August 19, 9.76 lakh shares (0.78% of total equity) were **UNPLEDGED** after a loan with RBL Bank was repaid. This reduced the promoter's pledged shares to 10.05% of equity. However, shortly after on August 21, 9.20...
Ajanta Pharma promoter Ravi Agrawal (via Ravi Agrawal Trust) has released a pledge on 6,910 equity shares on August 14, 2026. This move, cited as due to 'Excess Pledge,' slightly reduces the total promoter shares under pledge, signaling improved flexibility for the promoter group.
Ajanta Pharma: Promoter Ravi Agrawal (Trustee Ravi Agrawal Trust) has released a pledge on 54,796 equity shares of the company. The reason cited for this release is 'Excess Pledge'. This action typically reduces the promoter's overall pledged holding, which is often viewed positively by investors.